Whether Q4's Ag/Energy/Tech zero was timing or structural is the whole call.

• The miss. Q4 2025 organic growth printed 4% vs. 5.2% consensus — the first post-merger consensus miss — with Planetary Health Agriculture/Energy/Tech (36% of sales) flat in euros. Management blamed customer inventory build-down and FX; Berenberg, JPMorgan and Danske cut targets by DKK 20–68 inside a month.
• The resolution dates. Two prints settle the argument — the May 5 Q1 2026 interim and the August 20 H1 result. Ag/Energy/Tech above 4% in both keeps the timing-reversal read alive; a second sub-4% quarter confirms the structural read and re-opens the DKK 337 low.
• The asymmetry. At 33× consensus 2026 P/E the buyer pays for the timing read to be right. A clean 5%+ print mostly re-rates back toward the DKK 455 consensus target; a miss compresses the multiple before the 12–18 month bull setup has time to work.

Underlying earnings power is a decade-high — reported earnings hide it.

Operating cash flow of €1,222M was 2.1× reported net profit in 2025 because ~€235M a year of Chr. Hansen purchase-price-allocation amortisation hits reported EPS but never hits cash. Adjusted gross margin expanded 240bps y/y to 59.1% as cost synergies hit 100% run-rate a full year ahead of plan. For the 37–38% FY26 guide to hold, Ag/Energy/Tech has to reverse the Q4 flatline and capex absorbs the 50bps USD headwind management has flagged.

From a €2B pure-play enzymes house to a €4B biosolutions platform — and a quietly retired target book.

Before: Through 2022 Novozymes was a standalone enzymes pure-play with a clean financial framework — 5%+ organic CAGR, 26%+ EBIT margin before special items, 20%+ ROIC including goodwill, and a pledge to double sales by 2030 off the 2020 base. Shares hit DKK 500 in December 2021.

Pivot: On 29 January 2024 the company absorbed Chr. Hansen in the largest merger in Danish history, rebranded as Novonesis, and switched its headline KPI from EBIT margin to adjusted EBITDA margin. In August 2025 management launched the 2030 GROW plan — 6–9% organic CAGR, ~39% EBITDA margin, ~16% ROIC excluding goodwill — and the old 2025 targets were retired without reconciliation.

Today: Goodwill sits at €5.6B (34% of assets), net debt has jumped to €2.7B (1.9× EBITDA) after the €1.5B Feed Enzyme Alliance buy-out, and adj. ROIC including goodwill is 5.6% — below cost of capital. The question the next chapter answers: does the 10.1% ex-goodwill number climb toward mid-teens, or plateau?

Four 50/200 crosses in 18 months say the tape has no conviction.

• Trend. DKK 382 sits 4% below the 200-day, with a death cross still active from 17 September 2025. The stock is in the bottom 30% of its 52-week range — much closer to the DKK 337 low than the DKK 487 high.
• Momentum. RSI is 54 and has traced lower highs since the June 2025 peak; the MACD histogram flipped positive after the March DKK 352 low but is fading to zero. The late-March relief rally is losing force.
• Relative strength. Rebased to April 2023 = 100, Novonesis is at 116 versus SPY at 173 — a ~55-point gap that re-widened into the Q4 print. Volatility is benign at 24% — the tape is waiting for a catalyst, not being distributed.

Turkey is formally probing whether Novonesis' ~48% industrial-enzyme share is being abused.

• The probe. On 27 March 2025 the Turkish Competition Board fined Novonesis 0.1% of gross revenues plus a 0.15% daily penalty for "incomplete, incorrect, or misleading" responses to an Article 6 abuse-of-dominance investigation into industrial enzymes. The underlying case is open with no fixed timetable.
• Why it matters. Novonesis holds ~48% of global industrial enzymes and ~70% of dairy cultures after absorbing Chr. Hansen. Turkey is the first jurisdiction to formally investigate whether that position is being abused — a slow-burn regulatory risk that sits directly under the monopoly leg of the bull thesis.
• Insider tape. On 26 March 2026 — a month after the Q4 miss and mid-target-cut cycle — CSO Claus Crone Fuglsang sold DKK 2.3M of B-shares, the first material flagged insider sale post-print. Small in size; notable in timing.